These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 1852896)
1. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease. Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896 [TBL] [Abstract][Full Text] [Related]
2. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease]. Hesse WH; Rudofsky G; Peskar BA Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222 [TBL] [Abstract][Full Text] [Related]
3. Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease. Leonhardt A; Schweer H; Wolf D; Seyberth HW Br J Clin Pharmacol; 1992 Mar; 33(3):323-5. PubMed ID: 1576056 [TBL] [Abstract][Full Text] [Related]
4. On the metabolism of prostaglandin E1 administered intravenously to human volunteers. Peskar BA; Cawello W; Rogatti W; Rudofsky G J Physiol Pharmacol; 1991 Sep; 42(3):327-31. PubMed ID: 1793892 [TBL] [Abstract][Full Text] [Related]
5. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. Cawello W; Schweer H; Müller R; Bonn R; Seyberth HW Eur J Clin Pharmacol; 1994; 46(3):275-7. PubMed ID: 8070511 [TBL] [Abstract][Full Text] [Related]
6. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis. Leonhardt A; Krauss M; Gieler U; Schweer H; Happle R; Seyberth HW Br J Dermatol; 1997 Mar; 136(3):337-40. PubMed ID: 9115911 [TBL] [Abstract][Full Text] [Related]
7. Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry. Schweer H; Meese CO; Watzer B; Seyberth HW Biol Mass Spectrom; 1994 Mar; 23(3):165-70. PubMed ID: 8148408 [TBL] [Abstract][Full Text] [Related]
9. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease]. Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905 [TBL] [Abstract][Full Text] [Related]
10. Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance. Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):265-75. PubMed ID: 9653766 [TBL] [Abstract][Full Text] [Related]
11. Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation. Pallapies D; Peskar BA Thromb Res; 1993 Aug; 71(3):217-25. PubMed ID: 8211888 [TBL] [Abstract][Full Text] [Related]
12. Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma. Schweer H; Cawello W; Seyberth HW Prostaglandins Leukot Essent Fatty Acids; 1994 Dec; 51(6):401-5. PubMed ID: 7708804 [TBL] [Abstract][Full Text] [Related]
13. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit. Pieroni JP; Dray F; Pace-Asciak CR; McGiff JC J Pharmacol Exp Ther; 1988 Oct; 247(1):63-8. PubMed ID: 3139870 [TBL] [Abstract][Full Text] [Related]
14. Effects of intra-arterial prostaglandin E1 in patients with peripheral arterial occlusive disease. Creutzig A; Creutzig H; Alexander K Eur J Clin Invest; 1986 Dec; 16(6):480-5. PubMed ID: 3104047 [TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases]. Weiss T Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects. Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095 [TBL] [Abstract][Full Text] [Related]
17. Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung. Berry CN; Griffiths RJ; Hoult JR; Moore PK; Taylor GW Br J Pharmacol; 1986 Feb; 87(2):327-35. PubMed ID: 3955304 [TBL] [Abstract][Full Text] [Related]
18. Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Cawello W; Leonhardt A; Schweer H; Seyberth HW; Bonn R; Lomeli AL Br J Clin Pharmacol; 1995 Sep; 40(3):273-6. PubMed ID: 8527291 [TBL] [Abstract][Full Text] [Related]
19. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. Bothwell W; Verburg M; Wynalda M; Daniels EG; Fitzpatrick FA J Pharmacol Exp Ther; 1982 Feb; 220(2):229-35. PubMed ID: 6948952 [TBL] [Abstract][Full Text] [Related]
20. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value. Creutzig A; Arnold A; Caspary L; Thum J; Alexander K Angiology; 1995 May; 46(5):357-67. PubMed ID: 7741319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]